Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Cost of Revenue: 2015-2025

Historic Cost of Revenue for Aytu Biopharma (AYTU) over the last 11 years, with Jun 2025 value amounting to $20.9 million.

  • Aytu Biopharma's Cost of Revenue fell 5.96% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year decrease of 2.16%. This contributed to the annual value of $20.9 million for FY2025, which is 5.33% down from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Cost of Revenue is $20.9 million, which was down 5.33% from $22.1 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Cost of Revenue registered a high of $44.4 million during FY2022, and its lowest value of $20.9 million during FY2025.
  • For the 3-year period, Aytu Biopharma's Cost of Revenue averaged around $28.1 million, with its median value being $22.1 million (2024).
  • Per our database at Business Quant, Aytu Biopharma's Cost of Revenue skyrocketed by 219.49% in 2021 and then slumped by 46.72% in 2024.
  • Over the past 5 years, Aytu Biopharma's Cost of Revenue (Yearly) stood at $36.4 million in 2021, then rose by 21.83% to $44.4 million in 2022, then dropped by 6.62% to $41.4 million in 2023, then plummeted by 46.72% to $22.1 million in 2024, then fell by 5.33% to $20.9 million in 2025.